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Abstract 
In amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), spinal and lower brainstem motor neurons degen- 
erate, but some motor neuron subtypes are spared, including oculomotor neurons (OMNs). The mechanisms responsible 
for this selective degeneration are largely unknown, but the molecular signatures of resistant and vulnerable motor neurons 
are distinct and offer clues to neuronal resilience and susceptibility. Here, we demonstrate that healthy OMNs preferentially 
express Synaptotagmin 13 (SYT13) compared to spinal motor neurons. In end-stage ALS patients, SYT13 is enriched in 
both OMNs and the remaining relatively resilient spinal motor neurons compared to controls. Overexpression of SYT13 in 
ALS and SMA patient motor neurons in vitro improves their survival and increases axon lengths. Gene therapy with Syt13 
prolongs the lifespan of ALS mice by 14% and SMA mice by 50% by preserving motor neurons and delaying muscle den- 
ervation. SYT13 decreases endoplasmic reticulum stress and apoptosis of motor neurons, both in vitro and in vivo. Thus, 
SYT13 is a resilience factor that can protect motor neurons and a candidate therapeutic target across motor neuron diseases. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) and spinal muscular 
atrophy (SMA) are lethal neurodegenerative diseases char- 
acterized by a progressive loss of motor neurons in the spinal 
cord, brainstem, and cortex [9, 21]. However, some motor 
neurons are preserved throughout late stages of these dis- 
eases, including oculomotor neurons (OMNs), trochlear 
   neurons and neurons in the abducens, which regulate eye 
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movement as well as Onuf’s nuclei, which controls sphincter 
function. This has been demonstrated in both mouse mod- 
els [11, 24, 29, 32, 55] and in post-mortem tissues from 
patients [31, 35, 39, 60]. Notably, both the familial (f) and 
sporadic (s) forms of ALS and SMA share this pattern of 
selective motor neuron resistance [35, 61]. Consequently, 
eye movement and sphincter function remain relatively pre- 
served, even in the advanced stages of these diseases and 
ocular tracking have high utility for communication [35, 64]. 
This preservation across diseases indicates that differential 
vulnerability between motor neuron groups is largely inde- 
pendent on the cause of disease, and that mechanisms of 
vulnerability and resilience could be shared across diseases 
[9–11, 20]. Elucidation of the molecular basis of selective 
resistance may lead to the development of new therapies to 
prevent the relentless motor neuron loss. Previous studies of 
ALS and SMA [52] suggest that elements intrinsic to motor 
  
 
neurons are critical to the initiation and early progression of 
degeneration [6, 62]. We and others previously examined the 
gene expression patterns of vulnerable and resistant motor 
neuron groups and identified molecular differences that may 
account for their observed differential vulnerability [1, 4, 5, 
7, 10, 29, 33, 36, 56, 68]. 
To identify additional candidates of motor neuron resist- 
ance, we conducted a careful bioinformatics analysis of two 
previously published microarray data sets on isolated OMNs 
and spinal motor neurons in the rat and mouse. We identified 
24 genes, including synaptotagmin 13 (SYT13), with com- 
mon preferential expression in OMNs across species (mouse 
and rat) and ages (1 week and 8 weeks of age). RNA scope 
analysis in human control post-mortem tissues confirmed the 
localization and preferential expression of SYT13 in OMNs 
compared to spinal motor neurons also in man. RNA-seq 
analysis of motor neurons in end-stage ALS patient tissues 
demonstrated SYT13 enrichment in the remaining resilient 
neurons in both oculomotor nucleus and spinal cord com- 
pared to controls. 
SYT13 belongs to a family of synaptotagmins (SYTs) that 
are vesicular trafficking proteins important for synapsis and 
vesicle metabolism [65]. Unlike many other synaptotagmins, 
SYT13 binds to cellular membranes in a Ca2+-independent 
fashion [22]. Knowledge of SYT13 function is very limited, 
but SYT13 has been hypothesized to be involved in general 
vesicle trafficking and synaptic vesicle docking, facilitation 
of membrane fusion and exocytosis, and interactions with 
neurexin1 [22]. Based on the strong OMN expression of 
SYT13 in healthy controls, and its preferential expression 
in all remaining relatively resilient motor neurons in ALS 
patient tissues, as well as its functional implications in pro- 
cesses related to ALS and SMA, we pursued SYT13 in the 
context of motor neuron diseases. 
We investigated the effect of SYT13 on motor neurons 
from ALS and SMA patients and in transgenic mouse mod- 
els of ALS and SMA. Notably, we found that up-regulation 
of SYT13 induces motor neuron protection in  vitro and 
in vivo, prolonging the lifespan of both ALS and SMA mice, 
while decreasing apoptosis and ER stress and improving 
axon growth. Thus, our approach of using degeneration- 
resistant OMNs as a tool to identify motor neuron-protective 
molecules was validated and identified SYT13 as a candidate 
therapeutic target for motor neuron diseases. 
 
Materials and methods 
Ethics statement 
 
The studies involving human or animal tissues were con- 
ducted in compliance with the Code of Ethics of the World 
Medical Association (Declaration of Helsinki) and with 
national legislation and institutional guidelines. All ani- 
mal experiments were reviewed and received approval by 
the Italian Ministry of Health and Swedish animal ethical 
(Stockholms Norra Djurförsöksetiska nämnd) review boards. 
Ethical approval for the use of the human post-mortem speci- 
mens was granted from the regional ethical review board 
in Stockholm, Sweden (Regionala Etikprövningsnämnden, 
Stockholm, EPN). Human CNS samples were obtained from 
the Netherlands Brain Bank (NBB, www.brainbank.nl) and 
the National Disease Research Interchange (NDRI, www. 
ndriresource.org) with the written informed consent from 
the donors or next of kin (Table Supplementary 1, online 
resource). Human fibroblast cell lines were obtained from 
Eurobiobank with informed consent (ethical committee 
approved at the IRCCS Foundation Ca’ Granda Ospedale 
Maggiore Policlinico, Table Supplementary 2, online 
resource). 
RNA scope staining of human tissues 
 
To confirm the RNA-seq expression of SYT13, we used 
RNA scope [70]. RNA scope is a novel RNA in situ hybrid- 
ization technology with a unique probe design (double-Z 
design) that allows simultaneous signal amplification and 
background suppression to achieve single-molecule visu- 
alization. The technique is compatible with formalin-fixed, 
paraffin-embedded tissue specimens and can use conven- 
tional chromogenic dyes for brightfield microscopy or fluo- 
rescent dyes. Fresh-frozen midbrain or spinal cord samples 
from six controls subjects (Supplementary Table 1, online 
resource) were sectioned at 10 µm thickness in poly-l-lysine 
coated glass slides (Sigma, P0425) and kept at −80 °C. Prior 
to staining, slides were quickly thawed and fixed with fresh 
PFA (4% in PBS) for 1 h at 4 °C. The RNA scope 2.5 HD 
Assay—RED Kit (Cat. 322360) was used using manufac- 
turer recommendations. 
To set up the procedure, we tested a negative control 
probe against a bacterial gene (Cat. 310043, dapB-C1) and 
two different positive control probes against peptidylprolyl 
isomerase b (Cat No. 313901, PPIB-C1) and the vesicular 
acetylcholine transporter-member A3 (Cat No. 519321, 
VACHT-C1), (Supplementary Fig. 1, online resource). 
Once the assay was in place, sections were stained with a 
probe against Synaptotagmin 13 (Cat No. 552271, SYT13- 
C1). Slides were Nissl-counterstained with fresh 50% Gill 
No. 1 solution (Cat. GSH132-1L, Sigma-Aldrich) for 4 min, 
washed in water and dried for 15 min at 60 °C before mount- 
ing with Pertex (Cat. 00811, Histolab). 
For every sample (N = 3, for OMNs and spinal cord 
(SC) motor neurons), we imaged up to 30 random fields 
within the OMN region or the ventral horn in the spinal 
cord. Pictures were captured at 40× magnification using the 
bright field of a Leica microscope (DM6000/CTR6500 
  
 
 
and DFC310 FX camera). After randomization and decod- 
ing of all the images, cells were scored in a blinded fash- 
ion using a scale from 0 to 4, based on the number of 
dots (SYT13-RNA clouds) per cell using ImageJ (version 
1.48). Around 75 cells were scored per subject and region 
(OMN: 74.17 ± 36.39 and SC: 74.50 ± 23.43)  following 
the scoring guidelines from Advanced Cell Diagnostics 
(ACD, RNA scope 2.5 HD Assay—RED Kit User Manual 
page 16). In brief, the scoring was as follows: Score 0: 
No staining or less than 1 dot every 10 cells. Score 1: 1–3 
dots/cell. Score 2: 4–10 dots/cells, very few dot clusters. 
Score 3: > 10 dots/cell with < 10% of positive cells having 
dot clusters, and Score 4: > 10 dots/cell with > 10% of cells 
showing dot clusters. Investigators performing the quanti- 
fications were blinded to the target region (OMN and  SC). 
 
RNA sequencing of human OMNs and spinal cord 
motor neurons isolated by laser capture microscopy 
 
As motor neurons are easily identifiable by their distinct 
location in the oculomotor nucleus in the midbrain and 
ventral horn of the spinal cord and by their large soma 
sizes, human CNS tissues were subjected to a quick histo- 
logical (Nissl) staining based on the Arcturus Histogene 
Staining Kit protocol. Slides were placed into the slide 
holder of the microscope (Leica DM6000R/CTR6500) 
and captured using the Leica LMD7000 system. To avoid 
contamination by surrounding cells, cutting outlines 
were drawn closely around individual motor neurons. 
cDNA library preparation for sequencing on an Illumina 
HiSeq2000 sequencer was carried out with a slightly mod- 
ified version of the Smart-seq2 protocol [53, 54]. RNA- 
seq reads were mapped to the human reference genome 
hg38/GRCh38 (Ensembl version 81) using STAR [17] 
(version 2.4.1). To visualize the expression of genes/tran- 
scripts, Cufflinks [66] (version 2.2.1) was used to generate 
RPKM values with the parameter library-norm-method set 
as geometric. Quality control was conducted and samples 
with lower than 1 million reads or < 70% mapping ratio 
to the genome or < 7000 genes expressed ≥ 1 RPKM were 
removed from further analysis. Differential gene expres- 
sion analysis was performed on the read counts using 
DESeq2 [38]. Only genes with counts in a minimum of 
two samples were included for analysis. A gene was con- 
sidered differentially expressed at an adjusted P < 0.05. 
 
RNA‑seq data availability 
 
Fourteen new LCM-seq samples (corresponding to OMNs 
or spinal motor neurons from ALS patients) included in 
this study have been deposited in the GEO database under 
accession number GSE115130. Six control SC samples 
were previously submitted under the GEO accession 
GSE76514 [46] and an additional 32 control samples (both 
OMN and SC) were also published by our group under 
accession GSE93939 [2] (Supplementary Table 1, online 
resource). 
Animal models 
 
This study used adult male and female SOD1G93A mice 
(B6.Cg-Tg(SOD1-G93A)1Gur/J [28] as a model of fALS 
and non-transgenic littermates served as controls. This 
model shows early symptoms at 80 days of age. Mice 
were genotyped as previously described [47]. The triple- 
mutant SMA∆7 (FVB.Cg-Tg(SMN2*delta7)4299Ahmb 
Tg(SMN2)89Ahmb Smn1tm1Msd) transgenic model [37] 
was used as an in vivo model of SMA (male and female). 
The delta7 mutation refers to an artificial SMN2 cDNA that 
lacks exon 7, that is added to the Smn knockout mice that 
already express SMN2, to further extend the animal survival 
from 5–7 days to 15 days, thus making the mouse models 
more suitable for translational experiments. In particular, the 
Tg(SMN2*delta7)4299Ahmb allele is an SMA cDNA lack- 
ing exon 7, while the Tg(SMN2)89Ahmb allele is the entire 
human SMN2 gene. Heterozygous Smn knockout mice with 
the SMN2 transgenes were bred to obtain homozygous mice 
for the knockout Smn alleles (SMA mice, SMN2 +/ +;Smn 
Δ7 +/ +;mSmn −/ −) and pups were identified by genotyp- 
ing [37] (protocol approval 1007/2016 PR by Italian Minis- 
try of Health). All animals were kept according to standard 
conditions, including access of food and water at libitum and 
dark/light cycle of 12 h. 
Immunohistochemistry in rodent and human tissues 
 
Immunohistochemistry of murine tissues: mice were eutha- 
nized at 120 days of age (SOD1) or at P10 (SMA). Tissues 
were fixed in 4% paraformaldehyde for 24 h followed by 
20% sucrose solution overnight and frozen in liquid nitro- 
gen-cooled isopentane [2, 47]. Tissues were cryosectioned 
and mounted on gelatinized glass slides. Every 10th section 
(20 µm) was collected and analysed. For immunohistochem- 
istry, all sections were saturated with 10% bovine serum 
albumin and 0.3% Triton X-100 for 1 h at room temperature 
before incubation with primary antibodies overnight at 4 °C 
(see Supplementary Table 3, online resource for primary 
antibodies). The day after, slides were incubated with Alexa 
Fluor secondary antibodies (1:1000; Life Technologies). 
Lumbar spinal cord segments L3–L5 for ALS mice and 
L1–L2 for SMA mice (N = 3 mice/group) were stained with 
NeuroTrace 435/455 Blue Fluorescent Nissl Stain (1:100, 
Life Technologies), incubated for 1 h. Intercostal muscles 
for SMA mice and tibial anterior (TA) muscles for SOD1 
  
 
 
animals (N = 6 mice/group) were stained for presynaptic 
neurofilament medium (NFM, 1:250) and post-synaptic 
α-bungarotoxin 555 (BTX, 1: 200); LEICA LCS6 confocal 
microscope was used. Negative controls were performed for 
all stainings. 
For in vivo motor neuron quantification, lumbar spinal 
cord slices were stained with Nissl (conventional histology). 
Only neurons with an area ≥ 80 μm2 [14, 69] and located 
in a position congruent with that of motor neuron groups 
were counted on serial sections under transmitted light 
microscopy [47]. For NMJ quantification, a minimum of 100 
NMJs from each muscle/group were randomly selected and 
assessed under the microscope to determinate the number 
of denervated or degenerated junctions based on co-locali- 
zation of the two antibody signals. 
Immunohistochemistry of human tissues: characteristics 
of non-demented (ND) control post-mortem tissues used 
for immunohistochemical analysis are described in Sup- 
plementary Table 1, online resource. Tissues from NBB 
were embedded in paraffin and were sectioned (10 µm) on a 
sliding microtome. Tissues from NDRI were fixed in PFA, 
sequentially placed through sucrose gradients for cryopro- 
tection and sectioned (40 µm) on a freezing microtome. NBB 
tissue was deparaffinized and all tissues underwent antigen 
retrieval (0.01 M citric acid buffer, pH 6.0 for 20 min at 
95 °C) and blocking of endogenous peroxidases (3% H2O2 
in 50% methanol in PBS) prior to staining. Tissues were 
blocked and stained with primary antibodies for 2 days (Sup- 
plementary Table 3, online resource). Tissue was washed 
and incubated with a biotinylated secondary antibody 
(1:100; Vector Laboratories) for 3 h, with subsequent incu- 
bation in streptavidin–biotin complex (Vectastain ABC kit 
Elite, Vector laboratories) for 1 h and visualized by incuba- 
tion in 3,3′-diaminobenzidine solution (DAB, Vector Labo- 
ratories). Myers haematoxylin (Histolab) was utilized for 
counterstaining; tissue was dehydrated by sequential steps 
in increasing ethanol concentration and coverslipped using 
Mountex (Histolab). Brightfield images were captured using 
a Zeiss Axio Imager M1 Upright microscope. 
iPSC lines’ generation and motor neuron cultures 
 
Differentiation of human iPSCs into motor neurons: iPSC 
lines were reprogrammed from human fibroblasts as 
described in Supplementary Table 2, online resource. The 
cells were tested for Mycoplasma (MycoAlert kit, Lonza). 
ALS, SMA, and control iPSCs were differentiated into motor 
neurons using a multistep protocol, based on embryoid body 
formation and addition of specific cytokines, already 
described in the literature [42]. To monitor the proper acqui- 
sition of a motor neuron phenotype, cells were transduced 
with a lenti-Hb9::GFP construct [12, 40], fixed and stained 
for quantification utilizing established neuronal and motor 
neurons markers. Motor neuron cultures were transduced 
with a lentivirus-SYT13 or a null vector as the negative con- 
trol [63]. 
Induction of ALS-like toxicity: To model ALS conditions 
in vitro, iPSC-derived motor neurons were either co-cultured 
with toxic murine SOD1G93A astrocytes [16, 40] or exposed 
to glutamate excitotoxicity [18, 29]. For the SOD1G93A 
astrocyte toxicity assay, iPSCs-derived motor neurons were 
cultured on the bottom compartment of a transwell co- 
culture system in the presence of astrocytes (in the upper 
compartment) obtained either from SOD1G93A mice or WT 
mice. The porous membrane that separates the two compart- 
ments only allows diffusion of soluble molecules. Glial cells 
were obtained from embryonic spinal cords as previously 
described [2, 43] and seeded at 20,000 cells per cm2 [43]. To 
perform the excitotoxicity assay, motor neurons were main- 
tained for 7 days in a neurotrophin-deprived medium prior 
to the glutamate supplementation. Toxicity was induced by 
administration of 20 µM glutamate and 100 µM L-trans- 
Pyrrolidine-2,4-dicarboxylic acid (PDC) [2, 29]. Glutamate 
excitotoxicity was induced for 7 days, while the astrocyte co- 
culture assay lasted 3 weeks. Motor neurons were counted at 
the end of the toxic stimuli. 
SMA-like degeneration of human motor neurons: SMA 
patient-specific motor neurons derived from iPSCs present 
a cell-autonomous degeneration when maintained long-term 
in vitro (8 weeks) [13, 19, 48], allowing for SMA disease 
modelling. Motor neurons were counted at the end of the   
8 weeks. 
Immunocytochemistry and quantification of motor neu- 
ron cultures: Cells were fixed in 4% paraformaldehyde for 
10 min, blocked with 10% bovine serum albumin and 0.3% 
Triton X-100 in 1X PBS for 1 h at room temperature. Sam- 
ples were then incubated overnight in primary antibodies 
at 4 °C as described in Table S3. After washing, secondary 
antibodies were applied for 2 h at room temperature (Alexa 
Fluor 488 and Alexa Fluor 594, 1:500; Life Technologies). 
The anti-SYT13 antibody was visualized utilizing biotin- 
streptavidin amplification (anti-rabbit biotinylated antibody, 
1:400, DAKO; Cy3-streptavidin,1: 500, Sigma). Negative 
controls were performed for all stainings. Microphotographs 
were taken with a LEICA LCS2 confocal microscope. 
Motor neurons were quantified by selecting 10 ran- 
dom fields for each sample and counting the number of 
HB9 + cells. Morphometric and axonal length analyses were 
performed by measuring soma diameter and length distance 
between two points (one point from the soma and one on the 
distal axon) [13]. All analyses were carried out in double- 
blind fashion. 
ER  calcium analysis and imaging: Cells loaded with 
5 μM Fluo4 AM FLUO4 were acquired using a Zeiss Axio 
Observer.Z1 (Carl Zeiss, Jena—Germany) equipped with 
Hamamatsu EMCCD 9100-02 (Hamamatsu Photonics, 
  
 
Japan) and with a Zeiss FLUAR 40X oil immersion objec- 
tive (NA: 1.3). Exposure time was set to 50 ms and images 
were acquired every 5 s for at least 5 min. Images were 
collected at 14-bit depth and binning 2 (pixels resolution 
500 × 500) and analysed using ImageJ (NIH, Maryland— 
USA). Calcium variations were assessed by fluorescence 
measurements upon application of 20 µM thapsigargin in 
PBS depleted of CaCl2 and MgCl2 and calculated as changes 
in fluorescence intensity occurring in cell bodies as a fold 
increase above the normalized baseline (ΔF/F0). 
Western blot analysis of iPSC‑derived motor 
neurons 
 
Western blot analysis was performed as previously described 
[50]. Briefly, cells were sonicated on ice for 10 min in buffer 
supplemented with a protease and phosphatase inhibitor 
cocktail (Pierce) as described [13]. An amount of 60 µg was 
separated on a 10% sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis SDS–PAGE. Proteins were transferred 
on a nitrocellulose membrane and incubated with primary 
antibodies (Table Supplementary 3, online resource) over- 
night at 4 °C. Blots were then incubated in secondary anti- 
bodies (polyclonal goat anti-rabbit HRP 1:1000, Dako or 
1:2700, Life Technologies) and the immune complexes were 
revealed with a chemiluminescence assay (Amersham). The 
nitrocellulose membrane was stripped and re-probed with an 
anti-actin antibody (1:1000) as the loading control. 
Virus administration, behavioural and survival 
analysis in ALS and SMA animal models 
 
A total dosage of 11 × 1011 particles of AAV9 vector 
expressing Syt13 or Gfp was administered bilaterally into the 
hindlimb quadriceps and the thoracic muscles of SOD1G93A 
animals at 80 days of age (n = 12 for AAV9::Syt13, n = 5 
for AAV9::GFP). AAV9::null served as a control vector 
(n = 15). The same muscles were injected bilaterally also in 
SMA mice with a total dosage of 5 × 1010 particles. Here, 
injections were performed at P1 (n = 10 for AAV9::Syt13 
and n = 10 for AAV9::null). Animals were randomized using 
an assigned animal identification number. Power analysis 
using GraphPad was performed to calculate the number of 
mice needed to treat to detect a difference of 10% in lifespan 
with 80% power (β = 0.8) at a significance level of 0.05. 
Disease onset, progression, survival, weight and motor per- 
formance were monitored after AAV9::Syt13 or AAV9::null 
treatment. All tests were performed blinded to the mouse 
genotype and treatment. Motor functions were analyzed 
utilizing the righting test for SMA animals and the inverted 
grid assay for the SOD1G93A. Mice were sacrificed when 
unable to right themselves within 30 s when placed on either 
side [50]. 
Statistical analyses 
 
Statistical analyses were carried out utilizing StatsDirect 
for Windows (version 2.6.4) or GraphPad Prism 5 software. 
Multiple comparisons on a single data set were performed 
with one-way analysis of variance (ANOVA), and when sev- 
eral variables were taken into account, the two-way ANOVA 
was used, followed by appropriate post hoc analysis. Two- 
tailed, unpaired Student’s t test was employed to compare 
two groups. Differences in axonal length were investigated 
by the Kolmogorov–Smirnov test (https://www.physics.csbsj 
u.edu/stats/KS-test.n.plot_form.html). Kaplan–Meier log 
rank test and logistic regression analysis were used to com- 
pare lifespan and righting test, respectively. Chi-square test 
was used to determine statistical differences in NMJ inner- 
vation. All experiments were carried out at least in tripli- 
cate. The experimental results are shown as mean ± SEM 
or mean ± SD. The null hypothesis was rejected at the 0.05 
level. 
 
Results 
SYT13 is enriched in resistant motor neurons 
in healthy controls and ALS patients 
 
To further our understanding of neuronal vulnerability and 
resilience in ALS, we conducted a careful bioinformatics 
analysis comparing two microarray data sets on OMNs 
(resilient in ALS) and spinal motor neurons (vulnerable in 
ALS) from adult (8 week old) rats [30] and P7 mice [33]. 
We identified 24 differentially expressed genes (DEGs) com- 
monly enriched in OMNs across the two studies (Fig. 1a). 
SYT13 was among these 24 DEGs with strong preferential 
expression in OMNs (Fig. 1a–c), which we found particu- 
larly interesting, because SYTs are vesicular trafficking pro- 
teins important for synapses. To follow-up on this finding, 
we conducted RNA scope on human control post-mortem 
tissues from midbrain and spinal cord using a probe against 
human SYT13 to confirm the cellular localization of SYT13 
mRNA in OMNs and to quantify the levels at the single- 
molecule level. We counterstained with Nissl to identify 
motor neurons based on size and location. To validate the 
method, we used one negative control probe against the bac- 
terial gene dihydrodipicolinate (dapB), which, as expected, 
did not give any signal in human tissues (Supplementary 
Fig. 1a,b). We also used a general positive control probe 
against the enzyme peptidylprolyl cis–trans isomerase B 
(PPIB), which, as anticipated, gave positive signals in all 
cells, including motor neurons (Supplementary Fig. 1c, d, 
online resource), and a probe against vesicular acetylcho- 
line transporter (VACHT), which is specifically present in 
motor neurons and gave the expected signal (Supplementary 
  
 
 
 
 
 
Fig. 1e, f, online resource). Using the probe specific for 
SYT13, we found that SYT13 mRNA was highly expressed 
also in human OMNs (Fig. 1d, e, h), with lower levels in 
spinal motor neurons (Fig. 1f–h), validating the transcrip- 
tome data from rodents and showing the specificity of SYT13 
expression in human OMNs. We reasoned that, for SYT13 to 
be relevant to the preservation of particular motor neurons 
throughout the detrimental ALS disease process, the tran- 
script should be maintained or elevated in end-stage ALS. 
To investigate whether this was the case, we conducted laser 
capture microdissection coupled with polyA-based RNA 
sequencing (LCM-seq) [45, 46] on pools of individually iso- 
lated OMNs and spinal motor neurons from control and ALS 
patient tissues. Quality analysis of the sequenced neurons 
  
 
 
 
◂Fig. 1 SYT13 is enriched in resistant motor neurons in controls and 
ALS patients. a Venn diagram of the overlap in genes with higher 
expression in oculomotor neurons (OMNs) compared to spinal motor 
neurons (MNs) across two microarray studies conducted  in  adult 
rats [29] and P7 mice [33]. A total of 24 genes were preferential to 
OMNs across the two studies. b–c Heat maps of the 24 differentially 
expressed genes with preference for OMNs including adjusted P 
values and fold change. d–h RNA scope of human post-mortem tis- 
sues shows d, e the abundance of SYT13 mRNA in OMNs and f, g 
lower expression in spinal cord MNs, as quantified in (h). i, j RNA 
sequencing of human OMNs and spinal MNs from control and ALS 
patient tissues and analysis of the previously identified 24 genes with 
enriched expression in OMNs shows that i SYT13 is one of the most 
enriched transcripts in ALS OMNs, and that j SYT13 is enriched in 
the remaining spinal MNs in ALS patient tissues compared to control 
tissues. Analysis of RNA sequencing data shows higher expression  
of SYT13 in OMNs compared to spinal MNs in control individuals  
(k, ***P < 0.001) and demonstrates that SYT13 mRNA is induced in 
resistant OMNs in ALS (l, **P < 0.01). In addition, SYT13 is more 
highly expressed in the  remaining  relatively  resilient  spinal  MNs 
in ALS compared to control spinal MNs (m, ***P < 0.001). Scale 
bars = 2000 μm in d, f, 400 μm in e, g (30 μm in the insets) 
 
revealed that neuronal markers, including neurofilaments, 
tubulins, peripherin, and VACHT, were expressed at high 
levels across OMN and spinal motor neuron samples (Sup- 
plementary Fig. 1g, online resource). Glial markers were 
present, but at very low levels, and markers of oligodendro- 
cytes and microglia were absent in the majority of samples 
(Supplementary Fig. 1g, online resource). Principal com- 
ponent analysis (PCA) based on all genes expressed at > 1 
RPKM in five samples or more, separated OMNs and spi- 
nal motor neurons on the PC2 axis (Supplementary Fig. 1h, 
online resource). Analysis of HOX and PHOX gene expres- 
sion clustered OMNs away from spinal motor neurons based 
on their distinct anterior–posterior positions in the nervous 
system (Supplementary Fig. 2i, online resource). Notably, 
the human LCM-seq data showed that SYT13 mRNA was 
expressed at higher levels in OMNs than spinal motor neu- 
rons in control tissues (Fig. 1k, P < 0.001), confirming our 
RNA scope data. In-depth bioinformatics analysis of the 24 
DEGs enriched in rodent OMNs (Fig. 1a–c) showed that 
SYT13 was enriched in human OMNs in ALS compared to 
controls (Fig. 1i, l, P < 0.01). Notably, the remaining rela- 
tively resilient spinal motor neurons in ALS patient tissues 
also expressed significantly higher levels of SYT13 than 
motor neurons in general in control spinal cords (Fig. 1j, 
m, P < 0.001). Immunohistochemistry of SYT13 protein in 
human post-mortem tissues (Supplementary Table 1, online 
resource) demonstrated its presence in both OMNs and spi- 
nal motor neurons, with the staining in OMNs appearing 
more distinct (Supplementary Fig. 1j, k, online resource). 
Taken together, these data clearly show that SYT13 expres- 
sion is preferential to resistant OMNs, as well as relatively 
resilient spinal motor neurons remaining in end-stage ALS 
patient tissues, suggesting that SYT13 could play a benefi- 
cial role in these cells. 
 
SYT13 protects vulnerable ALS and SMA 
patient‑derived motor neurons 
 
Next, we investigated whether up-regulation of SYT13 could 
halt the degeneration of ALS and SMA patient motor neu- 
rons derived from induced pluripotent stem cells (iPSCs) 
(Supplementary Fig. S2a, online resource). The in vitro dif- 
ferentiation protocol gives rise to 80% motor neurons with 
a near absence of progenitor cells and proliferating cells, 
as few cells were positive for progenitor markers OLIG2 
and PAX6 and proliferation marker KI67, in line with 
the literature [42]. Motor neurons generated from human 
iPSCs, which were monitored by a lenti-Hb9::eGFP reporter 
construct, appeared healthy, had elongated neurites (Sup- 
plementary Fig. 2b, online resource) and demonstrated a 
significant increase in SYT13 mRNA and protein after trans- 
duction with a vector encoding the human SYT13 cDNA 
(Supplementary Fig. 2c, d, online resource, P < 0.001 and 
P < 0.05, respectively). To mimic non-cell-autonomous 
ALS degeneration in vitro, we used two different assays 
of progressive motor neuron death: co-culture with toxic 
SOD1G93A astrocytes or glutamate-induced excitotoxicity [2] 
(Fig. 2a, b). ALS and control motor neurons degenerated 
in response to either co-culture with SOD1G93A astrocytes 
or glutamate excitotoxicity (Fig. 2c, d, left panel). Overex- 
pression of SYT13 rendered motor neurons more resilient 
to ALS toxicity (P < 0.0001; Fig. 2c–f). We performed the 
same experiments in C9ORF72 iPSC-derived motor neurons 
(Supplementary Table 2, online resource). The overexpres- 
sion of SYT13 significantly increased survival (Supple- 
mentary Fig. 3, online resource, P < 0.01, two lines, three 
independent experiments/line), in line with the other ALS 
motor neuron lines tested. 
To test whether SYT13 overexpression could be pro- 
tective across motor neuron diseases, we also used SMA 
patient motor neurons, which degenerate due to the loss 
of functional SMN1. SMA motor neurons present with 
apparent cell-autonomous degeneration in vitro, which is 
evident after 8 weeks of culture [2, 13, 19]. Overexpres- 
sion of SYT13 in SMA motor neurons (mRNA: P < 0.001, 
protein: P < 0.05, Supplementary Fig. 2e, f, online resource) 
significantly improved their survival (P < 0.0001; Fig. 3a–c) 
and increased neurite length compared to null-treated SMA 
motor neurons (P < 0.0001; Fig. 3d). Thus, our data demon- 
strate that SYT13 can protect vulnerable motor neurons from 
degeneration across diseases. 
As SYT13 is implicated in vesicle trafficking, we 
investigated whether its up-regulation could modulate ER 
stress, a pathological event that occurs in both ALS and 
SMA [8, 44, 57, 58]. Immunofluorescence of ALS motor 
neuron cultures revealed a significant up-regula- tion of the 
ER stress markers, binding immunoglobulin protein (BiP) 
and phosphoeukaryotic initiation factor 2α 
  
 
 
 
 
 
Fig. 2 SYT13 protects human spinal  motor  neurons  from  ALS-  
like toxicity in vitro. (a, b) To model ALS disease, human spinal 
motor neurons (MNs) from healthy subjects (CTR) and sALS/fALS 
patients were exposed to toxic stimuli, comprising three weeks of co-
culture with SOD1G93A astrocytes (a) or 7 days of glutamate overload 
(b). c, d Representative images of ALS motor neurons (Hb9::GFP, 
green, DAPI, blue signal). The motor neurons were pro- gressively 
lost after co-culture with SOD1G93A astrocytes, whereas 
overexpression of SYT13 could rescue motor neuron survival (c, e; 
***P < 0.0001, F(8,126) = 116.1; one-way ANOVA). Exposure of 
cultures to glutamate also induced motor neuron degeneration, which 
could be rescued by overexpression of SYT13 (d, f; ***P < 0.0001, 
F(8,126) = 113.8; one-way ANOVA). Motor neurons positive for HB9 
and SYT13 were counted at the end of the toxic stimuli. Values are 
presented as means ± SEM from five independent experiments, three 
samples/group. Scale bar = 75 µm 
 
 
(pEIF2α) compared to control motor neurons (Fig. 4a, c, 
middle panel, P < 0.05 and P < 0.001, respectively). SMA 
motor neurons also presented an up-regulation of BIP and 
cleaved activating transcription factor 6 (ATF6) (Fig. 4e, g, 
middle panel, P < 0.001). The overexpression of SYT13 
reduced ER stress marker levels in both ALS and SMA 
motor neurons compared to null-treated motor neurons 
(Fig. 4a, right panel, Fig. 4b, d, P < 0.0001). Western blot 
analysis confirmed the results (Supplementary Fig. 4a, b, 
online resource). As activation of ER stress can lead to 
apoptosis, we investigated whether the observed increase 
in motor neuron survival after SYT13 overexpression was 
due to decreased apoptosis. Indeed, the activation of 
 
apoptotic protein cleaved caspase-3 (CASP3) and BAX 
were significantly reduced by overexpression of SYT13 in 
both ALS and SMA motor neurons, as shown by Western 
blot analysis (Supplementary Fig. 4a, b, online resource,  
P < 0.01 in ALS, P < 0.001 for  CASP3 and P < 0.01  for 
BAX  in SMA). Disruption of ER Ca2+  homeostasis  can 
play a direct role in the induction of ER stress and conse- 
quent apoptosis [15, 27]. Therefore, we evaluated ER Ca2+ 
storage in ALS and SMA motor neurons before and after 
SYT13 overexpression. We treated motor neurons with 
20 µM thapsigargin (TG) and measured the fluorescence 
intensity resulting from the release of ER Ca2+, which 
clearly demonstrated that SYT13 treatment restored the 
  
 
 
 
 
 
 
Fig. 3 SYT13 protects human spinal motor neurons from SMA 
degeneration in culture. a, b Representative  images  of  SMA spi- 
nal motor neurons (MNs) (Hb9::GFP, green; ChAT, red) with (b)  
and without (a) SYT13 infection. Scale bar= 75 µm. c The number   
of SMA motor neurons in long-term culture was significantly dimin- 
ished relative to control cells 8 weeks after differentiation. Overex- 
pression of SYT13 was protective to motor neurons (***P < 0.0001, 
F(3,56) = 236.4; one-way ANOVA).  Values  are  presented  as  
means ± SEM from five independent experiments, three samples/ 
group. d At eight weeks, untreated SMA motor neurons had shorter 
axon lengths than control cells. SMA motor neurons overexpressing 
SYT13 had longer axons than null SMA motor neurons (P < 0.001, 
two samples K–S test, five independent experiments) 
 
altered TG-evoked ER Ca2+ release (Fig. 4i) [15, 27]. 
Overall, our data suggest that SYT13 can protect human 
motor neurons from degeneration by mitigating patho- 
logical hallmarks of ALS and SMA, including ER stress, 
apoptosis and Ca2+ dysregulation. 
Syt13 prolongs the lifespan of SOD1G93A ALS mice 
by preserving motor neurons 
 
Next, we investigated whether delivery of Syt13 to 
SOD1G93A ALS mice could alleviate disease pathology 
and prolong survival. For this purpose, an AAV9 vector 
was administered bilaterally into the hindlimb quadriceps 
and thoracic muscles in early symptomatic mice (80 days 
old) at a total dosage of 11 × 1011 particles (Fig. 5a). Injec- 
tion of an AAV9::null vector served as the control. First, 
we demonstrated that an AAV9 encoding Syt13 and GFP 
(AAV9::Syt13-GFP) was capable of extensively trans- 
ducing ChAT+ motor neurons in the spinal cord after 
muscle injection (Fig. 5c). Forty-five percent of lumbar 
 
spinal motor neurons expressed GFP 2 weeks after injec- 
tion. We also showed that the Syt13-AAV9 effectively 
enhanced Syt13 expression in the spinal cords of treated 
mice (Fig. 5b, P < 0.01). AAV9::Syt13-treated SOD1G93A 
mice exhibited improved neuromuscular function, as eval- 
uated by the inverted grid test (Fig. 5d, m). Furthermore, 
the median survival of AAV9::Syt13 treated mice was 
extended by 20 days compared to AAV9::null treated ani- 
mals, a 14% gain (Fig. 5e, AAV9::null mice, 140 ± 5 days 
median survival; AAV9::Syt13  mice  160 ± 14  days; 
P = 0.0029). Neuropathological analyses of spinal cords 
from AAV9::Syt13 and AAV9::null treated mice at P120 
demonstrated that the AAV9::Syt13 treatment reduced 
motor neuron pathology. In particular, motor neuron loss 
was significantly reduced (Fig. 5f–h, P < 0.0001) and the 
axonal density in the L4 ventral root was improved (Fig. 5i, 
AAV9::Syt13 mice vs. AAV9::null mice, P < 0.0001). 
Next,  we  evaluated  muscle denervation in SOD1G93A 
mice injected with AAV9::Syt13. At P120, a clear preserva- 
tion of  innervation was  demonstrated by  staining against 
  
 
 
 
 
  
 
 
 
◂Fig. 4 SYT13 overexpression reduces stress in ALS and SMA motor 
neuron cultures. a, c Representative images of ALS and e, g SMA 
iPSC-derived motor neurons show an increase in stress marker stain- 
ing over time compared to control iPSC-motor neurons (CTR). Cells 
that express SYT13 had significantly reduced stress marker expres- 
sion (a, e: BiP red and SMI32 green; c: pEIF2αred and SMI32 green; 
g: ATF6 red and SMI32 green). In each panel, the inset (rectangle 
box) shows 1.5x magnification image of stress markers signal (red) of 
a select region indicated by the arrow (b, d, f, h). The immunoreac- 
tivity score of iPSC-derived motor neurons demonstrates that the sig- 
nal of the specific stress markers was increased in ALS/SMA motor 
neurons with respect to CTR motor neurons and reduced in SYT13- 
treated motor neurons with respect to null-treated samples (n = 20/ 
group, BiP ALS:  P < 0.001;  pEIF2α  ALS:  P < 0.001;  BiP  SMA: 
P < 0.001; ATF6 SMA: P < 0.001, one-way ANOVA). The immuno- 
reactivity score was quantified using ImageJ software. Values are pre- 
sented as means ± SEM. i Graphic showing the thapsigargin-induced 
calcium signal measured in C9ORF72, SOD, and SMA motor neu- 
rons with or without SYT13. SYT13 treatment restored the altered 
TG-evoked ER Ca2+release. Values are presented as  means± SD 
from five independent experiments, three samples/group. l Quantifi- 
cation of the area between 50 s (t1) and 150 s (t2), which is represent- 
ative of the calcium signal measured in C9ORF72, SOD, and SMA 
motor neurons with or without SYT13 
 
neurofilament medium and α-bungarotoxin (NF-M/BTX) 
in the tibialis anterior muscle of AAV9::Syt13 treated mice 
(Fig. 5j-l, P < 0.0001). Lastly, based on our in vitro data, we 
evaluated any modification of the activation of ER stress 
and apoptosis pathways after Syt13 overexpression in mouse 
spinal cords (Supplementary Fig. 5a, online resource), where 
we observed significantly reduced levels of ER stress and 
apoptotic markers. 
These data demonstrate that the transfer of a single 
OMN-restricted gene can lead to amelioration of ALS 
pathological hallmarks, including motor neuron degen- 
eration, the loss of innervation of skeletal muscles, and 
activation of ER stress and apoptosis. 
Syt13 improves motor behavior and prolongs 
survival of SMA mice 
 
Finally, we examined if the delivery of Syt13 to transgenic 
SMA∆7 mice could positively affect their disease phenotype 
and be protective across motor neuron diseases. We injected 
AAV9::Syt13 bilaterally into the hind limb quadriceps and 
thoracic muscles of presymptomatic SMA pups (P1) at a 
total dosage of 5 × 1010 viral particles. The overall positive 
effect of Syt13 transfer was apparent from gross inspection 
of AAV9::Syt13 treated SMA mice (Fig. 6l). Specifically, 
the mice presented with major improvements in neuromus- 
cular function as assessed by the righting reflex, particularly 
after P5, when all AAV9::null-treated mice were unable to 
perform the test (Fig. 6a, P < 0.01). AAV9::Syt13 delivery 
extended the survival of SMA mice with 6 days to a median 
life-span of 18 days, a 50% gain in survival compared to 
 
AAV9::null-treated animals (Fig. 6b, AAV9::null mice, 
12 days median survival; AAV9::Syt13 mice 18 days median 
survival; P = 0.0008). Quantitative neuropathological anal- 
ysis at P10 revealed that AAV9::Syt13 delivery preserved 
spinal motor neurons (Fig. 6c–e, P < 0.0001). AAV9::Syt13 
animals also presented with an increase in motor neuron 
soma size compared to AAV9::null mice (AAV9::Syt13 mice 
vs. AAV9::null mice P < 0.0001, Fig. 6f), indicative of a 
reduced loss of large motor neurons. 
Next, we analyzed muscle denervation in SMA mice 
treated with AAV9::Syt13. We detected a reduced level of 
denervation in the intercostal muscles at P10, as demon- 
strated by NF-M/BTX staining of AAV9::Syt13 treated mice 
compared to AAV9::null treated  animals  (Fig.  6g–i, 
P < 0.001). Moreover, Syt13 treatment reduced the expres- 
sion of markers of ER stress and apoptosis in the spinal 
cords of SMA mice, as evaluated by Western blot analy- 
sis (Supplementary Fig. 5b, online resource). 
Thus, Syt13 delivery was protective across motor neuron 
diseases that arise from distinct genetic causes. 
 
Discussion 
ALS and SMA are characterized by a selective loss of 
motor neurons, but OMNs that control extraocular muscles 
(EOMs) are resistant to degeneration in these fatal diseases 
[11, 24, 29, 32, 55]. Even stem cell-derived OMNs show 
an increased resilience to ALS-like toxicity compared to 
in vitro derived spinal motor neurons [3]. Identification of 
the cell intrinsic mechanisms responsible for this differential 
vulnerability could allow the development of therapies to 
prevent or slow down the progressive motor neuron loss. 
Notably, OMNs express several neuroprotective genes, 
including the calcium-regulating protein parvalbumin and 
insulin-like growth factor 2 (IGF-2) [10, 29, 56], which can 
protect mouse [29, 67] and human spinal motor neurons [2] 
from ALS- and SMA-like toxicity. IGF-2 could also prolong 
the lifespan of ALS mice by preserving motor neurons and 
inducing axonal regeneration [2]. In addition, GABA and 
glutamate receptor subunits selectively expressed in OMNs 
likely reduce their susceptibility to excitotoxicity [7, 10]. 
Moreover, Kaplan et al. (2014) demonstrated that matrix 
metalloproteinase-9 (MMP-9) was a vulnerability factor 
strongly expressed by a majority of cranial and spinal motor 
neurons, but almost absent from resilient OMNs and Onuf’s 
nuclei motor neurons. Partial reduction of MMP-9 levels in 
mutant SOD1 mice delayed muscle denervation and signifi- 
cantly extended lifespan [33]. These findings support our 
experimental strategy to identify therapeutic targets based 
on the analysis of molecular diversity between motor neuron 
populations that exhibit differential vulnerability to disease. 
  
 
 
 
 
 
Here, we identified SYT13 as a gene with preferential 
expression in OMNs compared to spinal motor neurons, and 
that is protective to all motor neurons in disease conditions. 
The preferential expression of SYT13 in OMN somas was 
preserved across mice, rats and humans. Notably, SYT13 
was expressed at even higher levels in OMNs from end- 
stage ALS patients than controls. SYT13 was also elevated 
in remaining relatively resilient spinal motor neurons in end- 
stage ALS patient tissues compared to control, indicating 
that SYT13 is either induced by the disease, or that cells with 
high sustained SYT13 expression are the ones remaining at 
late disease stages. Future single-cell LCM-seq analysis in 
control and ALS patient tissues will address this matter. 
Collectively, our data demonstrated that relatively disease- 
resistant motor neurons express SYT13, indicating that it 
could have a beneficial effect on these cells. 
Overexpression of SYT13 significantly protected ALS 
and SMA patient motor neurons from degeneration in mul- 
tiple toxicity assays. Thus, the protective action of SYT13 
expression seems to be independent of the etiology of degen- 
eration. This is similar to the vulnerability factor EphA4, the 
suppression of which has been shown to be beneficial across 
  
 
 
 
◂Fig. 5 Syt13 gene therapy extends the survival of SOD1G93A ALS 
mice by protecting motor neurons and preserving motor axons and 
neuromuscular junctions. a Schematic drawing of in vivo Syt13 deliv- 
ery. SOD1G93A mice were injected with AAV9::GFP, AAV9::Syt13, 
or AAV9::null at a total dose of 11 × 1011 vg bilaterally in the 
hindlimb quadriceps and thoracic muscles at 80 days of age (early 
symptomatic stage). b Increased levels of Syt13 expression were 
detected by RT-PCR in AAV9::Syt13 SOD1G93A spinal cord versus 
AAV9::null spinal cord. **P < 0.01 (t(4) = 5.533, t test). c Injection of 
AAV9::GFP leads to GFP expression within the spinal cord 2 weeks 
post-injection. Co-localization of GFP (green) with ChAT (red) 
demonstrated that motor neurons were efficiently transduced (n = 5 
mice). d The inverted grid performance of AAV9::Syt13-treated  
mice was significantly ameliorated with respect to AAV9::null mice 
(at P100, P126, and P141: P < 0.05, n = 6/group). Until 90 days all 
the mice were able to complete the test, holding the wire for 60 s, 
which is the baseline. e Kaplan–Meier survival curves demonstrates 
significantly extended median survival (by 20 days) in AAV9::Syt13 
treated mice (n = 12) compared to AAV9::null treated animals (n = 15 
AAV9::Syt13 mice, 160 ± 14 days median survival; AAV9::null mice 
140 ± 5 days; χ2 = 8.86, P = 0.0029, Kaplan–Meier log rank test). f,   
g Representative images of motor neurons with Neurotracer stain-  
ing (blue) in the lumbar segment of the spinal cords of AAV9::null 
(f) and AAV9::Syt13 (g) treated  mice  at  P120.  h,  i  Quantifica-  
tion of motor neurons (MNs) (h) and axons (i) in the lumbar spi- 
 
overexpression is involved in increased ER stress, suggest- 
ing a key role for this pathway in ALS [33]. Notably, in our 
experiments, SYT13 overexpression led to the suppression 
of ER stress in vitro and in vivo ALS and SMA models and 
could restore altered TG-evoked ER Ca2+ release in affected 
motor neurons. One of the final consequences of ER stress 
and disruption of ER Ca2+ homeostasis is the induction of 
apoptosis. In our in vitro and in vivo ALS and SMA disease 
models, we observed an elevation of apoptotic hallmarks, 
and these levels were reduced by SYT13 overexpression. 
The reduction of ER stress, altered Ca2+ homeostasis, and 
apoptosis after SYT13 overexpression clearly demonstrate 
the beneficial effect of this gene therapy. In addition to the 
improvement in cell survival, SYT13 expression had a ben- 
eficial effect on motor axon length in SMA patient cells. 
It is plausible that SYT13 participates in axonal develop- 
ment, neurite outgrowth, and axonal repair similar to SYT1 
and SNAP25 [23, 26, 51], but this remains to be further 
investigated. 
Syt13 gene therapy extended the survival of ALS G93A 
nal cords of AAV9::Syt13 and AAV9::null mice (mean± SEM) at 
 
(SOD1 ) and SMA (SMAΔ7) mice by preserving motor 
P120. Motor neuron  
and axon counts significantly increased in the AAV9::Syt13 treated 
group compared to the AAV9:null treated group (MNs: ***P < 
0.0001, F(2,87) = 323.96; one-way ANOVA, 
n = 30 slices counted/group, 3 mice/group; axons: ***P < 0.0001, 
F(2,33) = 224.16; n = 12 slices counted/group, 3 mice/group; one- 
way ANOVA). l, m Analysis of α-bungarotoxin (BTX, red) and 
neurofilament M (NF-M, green) in the NMJs of tibialis anterior 
muscles shows that AAV9::Syt13 treatment significantly increased 
the number of innervated NMJs in AAV9::Syt13 treated SOD1G93A 
mice (n, ***P < 0.0001, χ2(2) = 95.82, contingency test) compared to 
AAV9::null treated SOD1G93A mice (n = 100 NMJs analyzed for each 
animal, 6 mice/group). o Representative image of the performance of 
an AAV9::Syt13 treated SOD1G93A mouse in an inverted grid test at 
P126. Scale bar = 75 µm in b, 100 μm in f, g, and 50 μm in l, m 
 
ALS-causative SOD1 and TDP-43 mutations, as well as in 
SMN loss, with the main function being axon regeneration 
[68]. This across-causation functionality is highly beneficial 
from the perspective of therapeutic development, as mecha- 
nisms underlying motor neuron loss are largely unknown in 
sALS and could be different from one case to the next. Nota- 
bly, we have previously, in an RNA sequencing experiment 
on human dopamine neurons, identified SYT13 to be present 
also in this cell type [46]. Whether SYT13 is protective to 
dopamine neurons remains to be investigated. 
SYT13  lacks  a  Ca2+-binding site, suggesting that it is 
more likely involved in vesicle trafficking than in synap- 
tic regulation. Therefore, we speculate that SYT13 could 
also play a role in normal ER function, and that its loss 
could be potentially involved in ER stress. Up-regulation of 
ER stress is a pathological hallmark of ALS and SMA [34, 
44, 57, 58] and has been strongly implicated in selective 
motor neuron degeneration in these diseases [34, 41, 44, 
57, 58]. Interestingly, in vulnerable motor neurons, MMP-9 
neuron somas, axons, and the innervation of muscle end- 
plates. The preservation of innervation is likely the underly- 
ing reason for the improved neuromuscular function and sur- 
vival observed in treated animals. The protection of NMJs 
was more pronounced than the cell soma survival in vivo, 
and increased axon length was detected in vitro in SMA 
patient motor neurons, suggesting that Syt13 expression may 
act on axonal regeneration in vivo, similar to IGF-2 [2]. We 
delivered Syt13 at a time point when NMJs are already start- 
ing to be denervated in SOD1G93A mice [10]. Therefore, we 
speculate that Syt13 could be beneficial to motor neurons in 
symptomatic disease phases when more motor axons have 
started to retract from the muscle. 
Our results suggest Syt13 as a promising candidate for 
future therapeutic interventions in motor neuron diseases. 
Syt13 overexpression improved motor neuron survival and 
delayed muscle denervation in ALS and SMA mice, lead- 
ing to a 14% increase in lifespan of ALS mice and a 50% 
increase in SMA mice. Even a small increase in Syt13 
expression was sufficient to offer substantial benefits. Inter- 
estingly, Syt13 appears to act independent of the cause of 
disease in sALS, fALS, and SMA. 
The current absence of effective therapies in ALS reflects 
the small number of therapeutic targets with significant effi- 
cacy in in vivo models other than modulation of the causa- 
tive mutant SOD1 [9, 20]. The recently approved drugs for 
SMA, the antisense oligonucleotide Nusinersen and the gene 
therapy with AAV9-SMN1 [22, 46], represent a remarkable 
turning point for SMA therapy, with promising and excit- 
ing results. However, the beneficial effects can vary based 
on several factors, particularly the timing of treatment and 
disease severity. It is a well-documented fact that it is crucial 
  
 
 
 
 
Fig. 6 Syt13 gene therapy prolongs the survival of SMA mice by 
preserving motor neurons and promoting NMJ integrity. a The right- 
ing performance of AAV9::Syt13 mice improved significantly com- 
pared to AAV9::null mice (P < 0.01, n = 10 mice/group, logistic 
regression). The histogram shows the percentage of mice that can 
perform the test. b Kaplan–Meier survival curves demonstrates sig- 
nificantly extended survival (by 6 days) in AAV9::Syt13 mice (n = 10) 
compared to AAV9::null mice (n = 10; χ2 = 11.25, P = 0.0008). c, d 
Representative motor neurons (MNs) in the lumbar segment of the 
spinal cords of AAV9::null (c) and AAV9::Syt13 (d) mice (Nissl, 
blue). e, f Quantification  of  motor  neurons  (e)  and  their  size  (f) 
in the lumbar spinal cords of AAV9::Syt13 and AAV9::null mice 
(mean ± SEM).  Motor  neuron  number  and  dimension significantly 
 
to supplement SMN as early as possible in the treatment of 
SMA [25]. In addition, it is possible that increasing only 
SMN may not completely address the slow neurodegen- 
erative process that causes progressive functional decline 
beyond childhood in less severe SMA types [6]. Further- 
more, patients treated with SMN-based therapy may simply 
present delayed symptoms instead of rescued symptoms if 
recovery of the neuromuscular system is incomplete. Thus, 
finding SMN complementary/independent or downstream 
targets responsible for selective motor neuron  dysfunction 
increases in the AAV9::Syt13 treatment group compared to the 
AAV9::null treated group (number: ***P < 0.0001, F(2,87) = 96.88, 
n = 30 slices counted/group, three mice/group; size: ***P < 0.0001, 
F(2,87) = 33.30, n = 30 slices counted/group, three mice/group; one- 
way ANOVA). g, h Analysis of α-bungarotoxin (BTX, red) and neu- 
rofilament M (NFM, green) in the intercostal muscles shows that 
AAV9::Syt13 treatment significantly increases the number of inner- 
vated NMJs in the SMA mice compared to AAV9::null treatment (i, 
***P < 0.0001, χ2(2) = 75.34, n = 100 NMJs, six mice/group, contin- 
gency test). (l) Gross appearance of an AAV9::null mouse, which is 
not able to stand on four limbs, and a AAV9::Syt13 treated mouse at 
P10. Scale bar = 150 μm in c, d and 90 μm in g, h 
 
 
can be important for a comprehensive whole-lifespan thera- 
peutic approach that comprises symptomatic cases and all 
SMA clinical phenotypes. In this context, the neuroprotec- 
tive effect of SYT13 might warrant further exploration at the 
preclinical level in combination with SMN-based therapies. 
The most rational approach for genetic ALS forms appears to 
be gene therapy correction, particularly the selective reduc- 
tion of toxic RNAs and/or proteins [49, 59]. However, the 
vast majority of ALS cases are sporadic and of unknown ori- 
gin. Thus, finding a gene therapy approach to protect motor 
  
 
 
neurons by modulating gene expression of target genes, such 
as SYT13, is highly relevant from a therapeutic point of view 
in both sporadic and familial cases. 
Overall, our analysis demonstrates that deducing the bio- 
logical diversity of neuronal subpopulations can identify 
neuroprotective pathways for effective therapies in ALS and 
SMA, revealing SYT13 as a protective gene for motor neu- 
rons. Moreover, our strategy focused on genetic modification 
of neuronal subtypes displaying selective vulnerability may 
also have an impact in neurodegenerative diseases affecting 
other neuron classes. 
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